Inspection prep notes · Supply, manufacturing and packaging
Packaging and labeling mix-up prevention and line clearance
Also called: mix-up, labeling control, line clearance
FDA looks less at whether packaging and labeling procedures exist than at whether lines and labeling materials are actually controlled to prevent mix-ups. The findings below are quoted from warning letters and FDA 483s.
What inspectors cited
1Line clearance was not adequately performed
The tablets observed on and around the blister packaging machine did not belong to the current run, despite your batch records indicating that line clearance was performed.
FDA Warning Letter · Safecor Health, LLC · 2023-09-12 · View document
Additionally, your firm's voluntary recall of (b)(4) mg (b)(4) tablets due to (b)(4) mg tablets being found inside the bottle could be associated to inadequate line clearance of equipment prior to use.
FDA Warning Letter · Winder Laboratories, LLC · 2026-01-13
2Label usage was not recorded and reconciled
Drug labels are used and returned without any type of accountability, documentation or record keeping.
FDA 483 · SURETEC INNOVATIONS LLC · 2026-10-23 · View document
Your firm neither has label controls in place nor performs container label reconciliation for the repackaging of product prior to distribution.
FDA 483 · Edge Pharmacy Services, LLC · 2024-01-17 · View document
3Labeling materials were not stored under adequate control
Labels and other labeling materials are not stored separately with suitable identification for each different drug product, strength, dosage form or quantity of contents.
FDA 483 · L' Oreal Usa, Inc. · 2026-10-26 · View document
Personnel from your operations, manufacturing, kit packaging, supply chain, facilities, engineering, validation, quality control, and metrology departments have access to this label cage.
FDA 483 · Lantheus Medical Imaging, Inc. · 2026-10-23 · View document
4Materials were not segregated to prevent mix-ups
Improper segregation of drug products throughout your warehouse to prevent mix-ups.
FDA Warning Letter · Safrel Pharmaceuticals LLC · 2026-08-18
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, closures and labeling before disposition.
FDA 483 · L' Oreal Usa, Inc. · 2026-10-26 · View document
5Labels were not examined for correctness
Your procedure does not require inspectors to perform a visual inspection of finished drug products for the correct labeling.
FDA 483 · LeeSar Inc · 2026-11-05 · View document
You do not examine each batch of labels prior to labeling [redacted] vials for injection.
FDA 483 · Bello Bio LLC · 2026-10-27 · View document
Questions to check against your procedures
- Are packaging lines recorded as cleared, and the area around them, free of product from previous operations?
- Is line clearance of equipment before use adequate to keep product of another strength from being mixed in?
- Are the quantities of labels used and returned recorded and reconciled?
- Are labels and labeling materials stored separately with identification by product, strength, dosage form and quantity of contents, and is access to the storage area limited?
- Are unlabeled product and rejected labeling held in segregated areas so that mix-ups cannot occur?
- Is each batch of labels examined before labeling, and is finished product visually examined for correct labeling?
Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.